source
- Tempus AI to buy cancer test maker Personalis for $1.5 billionTempus AI announced it will acquire Personalis, a California-based company that offers a molecular residual disease test for cancer, in a transaction valued at $1.5 billion. The deal, priced at $1…
- Tempus AI to acquire cancer test maker Personalis for $1.5 billionTempus AI announced it will buy Personalis, a Fremont-based company that offers a molecular residual disease test for cancer, in a deal valued at $1.5 billion. The acquisition is expected to expan…